WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Wave Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.17+0.04 (+1.28%)
Close on Oct 19, 2026
- Market cap
- $646.71M
- P/E (TTM)
- –
- Dividend yield
- –
Wave Life Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Market Cap | $624.64M | $197.05M |
| Enterprise Value | $134.04M | $106.56M |
| PB Ratio | 1.38 | 2.14 |
| P/TBV Ratio | 1.38 | 2.46 |
Income (trailing twelve months)
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Operating Income | -$217.92M | -$21.44M |
| Pretax Income | -$202.47M | -$14.45M |
| Net Income | -$202.47M | -$22.46M |
| EBITDA | -$217.92M | -$16.91M |
| EPS (Diluted) | -$1.08 | -$0.83 |
Returns
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -68.3% | -53.1% |
| Return on Assets (ROA) | -50.0% | -41.0% |
| Return on Capital Employed (ROCE) | -42.9% | -37.8% |
Growth
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 127.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 16.3% | 6.42% |
Balance sheet
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $490.60M | $62.42M |
| Net Cash (Debt) | $490.60M | $15.68M |
| Net Cash Per Share | $2.49 | $0.65 |
| Equity (Book Value) | $453.52M | $48.79M |
| Book Value Per Share | $2.30 | $1.36 |
| Tangible Book Value | $453.52M | $23.06M |
| Working Capital | $456.69M | $75.77M |
Financial position
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Current Ratio | 9.99 | 3.30 |
| Quick Ratio | 9.67 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$191.58M | -$12.35M |
| Capital Expenditures | -$1.57M | -$1.06M |
| Free Cash Flow | -$193.15M | -$20.28M |
| FCF Per Share | -$0.98 | -$0.41 |
Efficiency
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Profits Per Employee | -$638.72K | -$732.08K |
| Employee Count | 317 | 73 |
Dividends and yields
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Earnings Yield | -32.4% | -21.2% |
| FCF Yield | -30.9% | -7.64% |
Shares
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 197,048,000 | 59,128,900 |
| Shares Change (YoY) | 21.2% | 11.1% |
| Shares Change (QoQ) | 0.49% | 0.54% |
| Float | 132,469,000 | 48,744,500 |
| Shares Held by Insiders | 32.8% | 11.8% |
| Shares Held by Institutions | 92.7% | 59.4% |
Taxes
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Wave Life Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -0.30 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Wave Life Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.